Eptinezumab treatment was associated with longer interictal headache/migraine periods which corresponded to greater improvements in patient-reported quality of life measures.

ABSTRACT:

Introduction

Longer periods between headache episodes (interictal periods) may provide greater time for the nervous system to reset from a previous episode, potentially improving disease status and health-related quality of life. This post hoc analysis evaluated this hypothesis by associating patients' longest interictal periods with improvements in patient-reported outcomes.

Methods

PROMISE-2 (NCT02974153) was a double-blind, placebo-controlled study evaluating eptinezumab for preventive treatment of chronic migraine (N = 1072). Daily electronic diary data from Weeks 1-12 and Weeks 1-24 were used to identify interictal periods, defined as days between headache episodes. For each patient, the longest interictal period within these intervals was identified and categorized (1-

SUBMITTER: Tepper SJ 

PROVIDER: S-EPMC11638385 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature